Cornelis E.C.A. Hop, Mark J. Cole, Ralph E. Davidson, David B. Duignan, James Federico, John S. Janiszewski, Kelly Jenkins, Suzanne Krueger, Rebecca Lebowitz, Theodore E. Liston, Walter Mitchell, Mark Snyder, Stefan J. Steyn, John R. Soglia, Christine Taylor, Matt D. Troutman, John Umland, Michael West, Kevin M. Whalen, Veronica Zelesky and Sabrina X. Zhao
Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADmezME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.